Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOV-001 in Healthy Volunteers and Enteric Hyperoxaluria
NCT04909723Phase 2Terminated
- Sponsor
- Novome Biotechnologies
- Start
- Jun 2021
- Primary completion
- Nov 2022
- Modality
- Live Biotherapeutic Products
- Countries
- 2
01
Overview
A Phase 2 trial of NOV-001 in enteric hyperoxaluria (EH), sponsored by Novome Biotechnologies. Started Jun 2021; status: terminated.
02
Drugs
NOV-001
03
Conditions
enteric hyperoxaluria (EH)
Beyond the preview
Go deeper on NCT04909723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04909723.